Trial Profile

A Phase 1/2 Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Binimetinib (Primary) ; Crizotinib (Primary) ; Darovasertib (Primary)
Indications Colorectal cancer; Malignant melanoma; Skin cancer; Solid tumours; Uveal melanoma
Focus Adverse reactions; Pharmacokinetics; Proof of concept; Registrational; Therapeutic Use
Sponsors IDEAYA Biosciences

Most Recent Events

31 Mar 2025 According to an IDEAYA Biosciences media release, trial data to be presented at medical conferences in mid-year 2025 and the second half of 2025.
13 Feb 2025 According to an IDEAYA Biosciences media release, phase 2 median overall survival (OS) readout from study IDE196-001 in ~40 1L MUM patients targeted in 2025.
13 Nov 2024 Planned number of patients changed from 278 to 341.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com